基因治疗新生血管性年龄相关性黄斑变性的疗效与安全性:系统综述与荟萃分析
该系统综述与荟萃分析纳入8项前瞻性干预研究共203例接受基因治疗的nAMD患者,评估基因治疗的安全性与临床疗效。主要分析显示最佳矫正视力无显著改善(MD 0.54 ETDRS字母,95%CI -7.38至8.46),但中央亚区厚度显著降低(MD 37.13 µm,95%CI 26.63-47.62),约44%治疗眼需补救抗VEGF注射。安全性事件累积概率低至中等,证据支持基因治疗作为减轻治疗负担的辅助手段而非替代常规抗VEGF治疗。
要点
- 基因治疗未显示显著BCVA改善,但CST显著降低37.13 µm,提示解剖学获益。
- 约44%治疗眼仍需补救抗VEGF注射,治疗负担减轻作用有限。
- 安全性事件累积概率低至中等,但受模型、终点和载体平台影响。
核心结论
- 基因治疗对nAMD显示鼓舞人心的解剖学疗效和可管理的短中期安全性信号,但缺乏一致的功能性视力改善。
- 当前证据支持基因治疗作为减轻治疗负担的辅助角色,而非替代常规抗VEGF治疗。
研究设计与样本
- 遵循PRISMA指南的系统综述与荟萃分析,检索PubMed、Embase、Scopus、Web of Science、Google Scholar和Cochrane Library从建库至2026年2月1日。
- 纳入8项前瞻性干预临床研究共203例接受基因治疗的nAMD参与者,包括随机早期试验和开放标签剂量递增队列。
- 采用RoB 2和ROBINS-I工具评估偏倚风险,使用限制性最大似然多水平随机效应荟萃分析。
主要发现
- 主要多水平REML分析显示BCVA无显著合并改善(MD 0.54 ETDRS字母;95%CI -7.38至8.46)。
- CST显示显著解剖学降低(MD 37.13 µm;95%CI 26.63-47.62)。
- 约44%治疗眼需要补救抗VEGF注射。
- 安全性结局显示低至中等累积事件概率,但估计值因模型、终点和载体平台而异。
- BCVA和CST检测到发表偏倚,但大多数安全性结局的发表偏倚极小。
临床怎么用
- 基因治疗可作为减轻治疗负担的辅助手段,但不应替代常规抗VEGF治疗。
- 需关注患者仍需补救抗VEGF注射的可能性,约44%治疗眼需要补救。
- 短中期安全性信号可管理,但长期安全性需进一步验证。
局限性
- 证据强度受限于早期阶段设计、小样本量和临床异质性。
- 需要正在进行的3期试验来确定长期疗效和临床定位。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TOPIC: This systematic review and meta-analysis evaluated whether gene therapy provides safe and clinically meaningful efficacy for patients with neovascular age-related macular degeneration (nAMD). The clinical question addressed outcomes in patients with nAMD receiving gene therapy (primarily adeno-associated virus-based anti-vascular endothelial growth factor (anti-VEGF) constructs) compared with baseline or standard care contexts, focusing on visual acuity, anatomical response, treatment burden, and safety. Anti-VEGF intravitreal injections remain the current standard of care but require frequent administration and long-term adherence. CLINICAL RELEVANCE: nAMD is a major cause of irreversible vision loss in older adults and imposes substantial treatment burden due to repeated injections. Gene therapy aims to achieve sustained intraocular therapeutic protein expression after a single or infrequent administration, potentially reducing injection frequency while maintaining disease control. Establishing safety and functional efficacy is critical before translation into routine retinal practice. METHODS: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, databases (PubMed, Embase, Scopus, Web of Science, Google Scholar, and Cochrane Library) were searched from inception to February 1, 2026. Eligible studies were prospective interventional clinical studies evaluating gene therapy in neovascular age-related macular degeneration, including randomized early-phase trials and open-label dose-escalation cohorts. Primary outcomes included best-corrected visual acuity (BCVA), central subfield thickness (CST), rescue anti-VEGF requirement, mortality, and adverse events (AEs). Risk of bias was assessed using the revised Cochrane Risk of Bias tool version 2 (RoB 2) and Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) tools. Multilevel random-effects meta-analyses using restricted maximum likelihood (REML) accounted for clustering of multiarm cohorts. RESULTS: Eight prospective interventional studies comprising 203 treated participants were included, including randomized early-phase trials and open-label dose-escalation cohorts. The primary multilevel REML analysis showed no significant pooled BCVA improvement (mean difference (MD) 0.54 Early Treatment Diabetic Retinopathy Study (ETDRS) letters; 95% confidence interval (CI), -7.38 to 8.46), despite favorable fixed-effect sensitivity estimates. CST demonstrated significant anatomical reduction (MD 37.13 µm; 95% CI, 26.63-47.62). Approximately 44% of treated eyes required rescue anti-VEGF injections. Safety outcomes showed low-to-moderate cumulative event probabilities, although estimates varied by model, endpoint, and vector platform. Publication bias was detected for BCVA and CST but was minimal for most safety outcomes. CONCLUSION: Gene therapy for neovascular age-related macular degeneration demonstrates encouraging anatomical efficacy and manageable short- to midterm safety signals but lacks consistent functional visual improvement. Current evidence supports a treatment-burden-reducing adjunctive role rather than replacement of conventional anti-VEGF therapy. Evidence strength is limited by early-phase designs, small sample sizes, and clinical heterogeneity; ongoing phase 3 trials are required to define long-term efficacy and clinical positioning.
引用
- Chen KY, Chan HC, Chan CM, et al. Efficacy and Safety of Gene Therapy for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis. Am J Ophthalmol. 2026. PMID: 41941952. doi:10.1016/j.ajo.2026.04.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。